15

20

# 1. A compound of Formula (I):

or a pharmaceutically acceptable salt or solvate thereof wherein:

### Ar represents:

a substituted or unsubstituted, (preferably aromatic), carbocyclic or heterocyclic group, said carbocyclic or heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, any heteroatoms being selected from N, O and S, any substituents on the Ar group being independently selected from the group consisting of:

(a) Cl, (b) Br, (c) F, (d) OH, (e) NO<sub>2</sub>, (f) CF<sub>3</sub>, (g) C<sub>1-4</sub> lower alkyl (in particular CH<sub>3</sub>), (h) SCH<sub>3</sub>, (i) NHCOCH<sub>3</sub>, (j) N(R<sup>6</sup>)(R<sup>8</sup>) wherein R<sup>6</sup> and R<sup>6</sup> are the same or different and each represents H or lower C<sub>1-4</sub> alkyl, (k) OR<sup>10</sup> wherein R<sup>10</sup> represents a saturated or unsaturated lower C<sub>1-8</sub> straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

Cl, Br, F, OMe, NO<sub>2</sub> and CF<sub>3</sub>,

and (I) -OCOR<sup>11</sup>, wherein R<sup>11</sup> represents a saturated or unsaturated lower C<sub>1-6</sub> straight or branched hydrocarbyl group or a phenyl group;

#### R represents

OH, OR<sup>10</sup> or OCOR<sup>11</sup>, wherein R<sup>10</sup> and R<sup>11</sup> are as defined above; and R<sup>1</sup> represents H or a lower C<sub>1.6</sub> straight or branched hydrocarbyl group which may be

25

30

5

unsubstituted or substituted by 1, 2 or 3 substituents selected from CI, Br, F, OMe, NO<sub>2</sub> and CF<sub>3</sub>.

- 2. A compound according to Claim 1 wherein Ar represents a substituted or unsubstituted (preferably aromatic), heterocyclic group said heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, the heteroatoms being selected from N, O and S, and any substituents on the Ar group being independently selected from the group consisting of:
  - (a) CI, (b) Br, (c) F, (d) OH, (e)  $NO_2$ , (f)  $CF_3$ , (g)  $C_{14}$  lower alkyl (in particular  $CH_3$ ), (h)  $SCH_3$ , (i)  $NHCOCH_3$ , (j)  $N(R^6)(R^8)$  wherein  $R^6$  and  $R^8$  are the same or different and each represents H or lower  $C_{14}$  alkyl, (k)  $OR^{10}$  wherein  $R^{10}$  represents a saturated or unsaturated lower  $C_{18}$  straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

CI, Br, F, OMe, NO2 and CF3,

- and (I) -OCOR $^{11}$ , wherein R $^{11}$  represents a saturated or unsaturated lower C $_{1-6}$  straight or branched hydrocarbyl group or a phenyl group.
- 3. A compound according to any preceding claim wherein the Ar group is a substituted or unsubstituted (preferably aromatic), heterocyclic group, said heterocyclic group containing from 5 to 10 ring atoms, wherein at least one of the ring atoms is a nitrogen atom and any substituent on the ring is as defined as for Claim 1.
  - 4. A compound according to any preceding claim wherein Ar represents pyridyl or indolyl.
  - 5. A compound according to Claim 1 wherein Ar represents a substituted or unsubstituted (preferably aromatic), carbocyclic group, said carbocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein

20

25

30

U

the or each ring contains 5 or 6 ring atoms, and any substituents on the Argroup being independently selected from the group consisting of:

(a) Cl, (b) Br, (c) F, (d) OH, (e) NO<sub>2</sub>, (f) CF<sub>3</sub>, (g) C<sub>14</sub> lower alkyl (in particular CH<sub>3</sub>), (h) SCH<sub>3</sub>, (i) NHCOCH<sub>3</sub>, (j) N(R<sup>6</sup>)(R<sup>6</sup>) wherein R<sup>6</sup> and R<sup>8</sup> are the same or different and each represents H or lower C<sub>14</sub> alkyl, (k) OR<sup>10</sup> wherein R<sup>10</sup> represents a saturated or unsaturated lower C1.6 straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

CI, Br, F, OMe, NO<sub>2</sub> and CF<sub>3</sub>, and (I) -OCOR11, wherein R11 represents a saturated or unsaturated lower C16 straight or branched hydrocarbyl group or a phenyl group.

- A compound according to any preceding claim wherein any substituents on the Ar group are selected from the group consisting of: NHCOCH<sub>3</sub>, N(R<sup>6</sup>)(R<sup>6</sup>), OR<sup>10</sup> and -OCOR11, wherein R6, R8, R10 and R11 are as defined in Claim 1.
- 7. A compound according to any preceding claim wherein Ar is substituted with one or more OR10 groups, wherein R10 represents a saturated or unsaturated lower C1.6 straight or branched hydrocarbyl group.
- A compound according to Claim 7 wherein R<sup>10</sup> represents methyl. 8.
- 9. A compound according to any of Claims 5 to 8 wherein Ar is selected from phenyl or phenyl substituted with 1, 2 or 3 methoxy groups.
- 10. A compound according to any preceding claim wherein R represents an unsaturated lower C<sub>1-6</sub> straight or branched hydrocarbyl group.
- A compound according to Claim 10 wherein R represents OCH=C(CH<sub>3</sub>)<sub>2</sub>, 11. OCH<sub>2</sub>CMe=CH<sub>2</sub>, OCH<sub>2</sub>CH=CH<sub>2</sub> or OCH<sub>2</sub>C=CH.

- 12. A compound according to Claim 1 wherein Ar is selected from phenyl, trimethoxyphenyl, 3-pyridyl, 4-pyridyl or 3-indolyl; and R is selected from OCH=C(CH<sub>3</sub>)<sub>2</sub>, OCH<sub>2</sub>CMe=CH<sub>2</sub>, OCH<sub>2</sub>CH=CH<sub>2</sub> or OCH<sub>2</sub>C=CH.
- 13. A compound according to any preceding claim wherein R¹ represents a lower C<sub>1-6</sub> straight or branched hydrocarbyl group.
- 14. A compound according to Claim 13 wherein R¹ represents methyl.
- 15. A compound according to Claim 5 wherein:

### Ar represents

phenyl, which may be unsubstituted or substituted by one, two or three substituents independently selected from

CI, Br, F, OMe, NO<sub>2</sub>, CF<sub>3</sub>, C<sub>1-4</sub> lower alkyl (in particular CH<sub>3</sub>), NMe<sub>2</sub>, NEt<sub>2</sub>, SCH<sub>3</sub> and NHCOCH<sub>3</sub>;

thienyl, 2-furyl, 3-pyridyl, 4-pyridyl or indolyl.

## R represents

OH or OCH<sub>2</sub>R<sup>1</sup>, wherein R<sup>1</sup> is selected from -CH=CMe<sub>2</sub>, -CMe=CH<sub>2</sub>, -CH=CH<sub>2</sub> and -C=CH.

- 16. A compound according to any preceding claim wherein R<sup>6</sup> and R<sup>8</sup> are the same or different and each represents H or lower C<sub>1-4</sub> alkyl.
- 17. A compound according to any preceding claim wherein R<sup>10</sup> and R<sup>11</sup> represents a saturated or unsaturated C<sub>1-8</sub> straight chain or branched hydrocarbyl group.
- 18. A compound according to any Claim 17 wherein R<sup>10</sup> and R<sup>11</sup> are selected from methyl, ethyl, n-propyl or isopropyl.

10

20

25

5

30

20

25

5 .

- 19. A compound of Formula (I) selected from the following:
- 1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one (VIB 106),
- 1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 119),
- 1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)-propen-1-one (VIB 120),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one VIB 122),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 121),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one (VIB 162),
- 1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)propen-1-one (VIB 123),
- .1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 158),
- 1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one (VIB 161),
- 1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one (VIB 159),
- 1-[4-methyl-7-(allyloxy)coumarin-3-yl]-3-(3,4,5-trimethoxyphenyl)propen-1-one (VIB 160),
- 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)propen-1 one (VIB 126),
- 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 124),
- 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one (VIB 125), and
- 1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one (VIB 163).
- 20. A compound of Formula (I) as defined in any preceding claim for use as a antiproliferative medicament.

- 21. Use of a compound of Formula (I) as defined in any preceding claim for the manufacture of a medicament for the treatment or prevention of neoplasms.
- 22. Use according to Claim 21 wherein the neoplasms are located in the uterus, ovary or breast.
- 23. Use according to Claim 21 or 22 of a compound of Formula (I) for the manufacture of a medicament for the treatment of paclitaxel- and docetaxel-resistant cancer cells.
- 24. Use according to any of Claims 21 to 23 of a compound of Formula (I) in the manufacture of an antiproliferative medicament for combination therapy.
- 25. Use according to Claim 24 of a compound of Formula (I) in the manufacture of an antiproliferative medicament in combination with one or more antineoplastic agents.
- 26. The use according to Claim 25 wherein the antineoplastic agent comprises paclitaxel or docetaxel.
- 27. The use according to Claim 19 in the manufacture of a medicament for the treatment or prevention of menopausal disorders and osteoporosis.
- 28. A pharmaceutical composition comprising one of more of the compounds of Formula (I) as defined in any preceding claim, in combination with one or more pharmaceutically acceptable excipients.
- 29. A pharmaceutical composition according to Claim 28 further comprising one or more antineoplastic agents.

15

20

25

30. A pharmaceutical composition according to Claim 29 wherein the antineoplastic agent is selected from paclitaxel or docetaxel.